Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Proposal for a European Media Freedom Act

The European Commission has presented a proposal for new legislation which aims to protect journalists and media companies and combat disinformation.
September 26, 2022

The European Commission proposes a new Single Market Emergency Instrument

On 19 September 2022, the Commission adopted a proposal for a new regulation on an emergency instrument for the Single Market. Following the Covid-19 pandemic and other crises in the last years, the Union has seen internal entry restrictions, unpredictable rules and supply disruptions which, according to the Commission, have highlighted that there are structural shortcomings in the EU legal framework on the Single Market. The proposed emergency instrument aims to preserve the free movement of goods, services and persons and to ensure the availability of essential goods and services in the event of future emergencies.
September 22, 2022

New partners and counsels appointed at Vinge’s Gothenburg office

Ninos Aho has been appointed partner at Vinge’s Gothenburg office, as of 1 January 2023. In addition, advokat Petronella Hallberg and advokat Martin E Svanberg have been appointed as counsels, also as of 1 January 2023.
August 30, 2022